Compare STRO & PSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STRO | PSBD |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | United States | United States |
| Employees | 133 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 381.1M | 325.5M |
| IPO Year | N/A | 2019 |
| Metric | STRO | PSBD |
|---|---|---|
| Price | $22.94 | $9.53 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 9 |
| Target Price | ★ $31.33 | $12.33 |
| AVG Volume (30 Days) | ★ 441.4K | 205.0K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 15.02% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.66 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.69 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.72 | $9.34 |
| 52 Week High | $43.85 | $14.43 |
| Indicator | STRO | PSBD |
|---|---|---|
| Relative Strength Index (RSI) | 34.27 | 28.73 |
| Support Level | $19.11 | $9.34 |
| Resistance Level | $27.96 | $11.08 |
| Average True Range (ATR) | 2.14 | 0.30 |
| MACD | -0.55 | -0.07 |
| Stochastic Oscillator | 10.83 | 11.90 |
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.